{"title":"The New SNOMED CT International Medicinal Product Model.","authors":"Olivier Bodenreider, Julie James","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To present the new SNOMED CT international medicinal product model.</p><p><strong>Methods: </strong>We present the main elements of the model, with focus on types of entities and their interrelations, definitional attributes for clinical drugs, and categories of groupers.</p><p><strong>Results: </strong>We present the status of implementation as of July 2018 and illustrate differences between the original and new models through an example.</p><p><strong>Conclusions: </strong>Benefits of the new medicinal product model include comprehensive representation of clinical drugs, logical definitions with necessary and sufficient conditions for all medicinal product entities, better high-level organization through distinct categories of groupers, and compliance with international standards.</p>","PeriodicalId":72554,"journal":{"name":"CEUR workshop proceedings","volume":"2285 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584358/pdf/nihms-1840460.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CEUR workshop proceedings","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To present the new SNOMED CT international medicinal product model.
Methods: We present the main elements of the model, with focus on types of entities and their interrelations, definitional attributes for clinical drugs, and categories of groupers.
Results: We present the status of implementation as of July 2018 and illustrate differences between the original and new models through an example.
Conclusions: Benefits of the new medicinal product model include comprehensive representation of clinical drugs, logical definitions with necessary and sufficient conditions for all medicinal product entities, better high-level organization through distinct categories of groupers, and compliance with international standards.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
